Atropos Health translates real-world clinical date into personalized real-world evidence and insights announced its partnership with SEQESTER today (December 14).
Healthcare and life science organizations which use the Atropos Health Evidence Network can establish turnkey patient registries to accelerate evidence generation. This process, the companies say, previously costing millions and requiring up to a year, marks a significant leap forward in speed-to-insight for many underrepresented populations served by registry-based research.
Atropos Health says the partnership builds on its mission of ‘rapidly improving evidence-based insights’ on real-world data to drive better patient outcomes as well as accelerate drug development. Ultimately it says it will save healthcare and life sciences organizations significant time and expense.
Personalized registries
The companies say that members of the Atropos Health Evidence Network will be able to use SEQESTER to create personalized registries that capture the voice of the patient while generating real-world evidence from existing registries in less than 48 hours, closing both the registry time to set-up and evidence time-to-insight.
Ardy Arianpour, co-founder and CEO of SEQSTER, said: “Our partnership with Atropos Health furthers our commitment to progressing healthcare with novel technology and providing real world data and rapid evidence generation accessible to both patients and partners.
“SEQSTER’s operating system acts as a digital front door for patients and researchers.
“By powering the Atropos Health Evidence Network with longitudinal patient data, we’ll be able to save health systems and life science enterprises cost and time on registry deployment, making it a seamless process for all stakeholders. Now, we can deliver real-time, real-world data and layer in AI to accelerate drug discovery and provide deep insights for our pharma and health system customers.”
Querying diverse patient populations
The registries encompass real-time updates to medical records, patient reported outcomes (PROs), and tools for querying diverse patient populations. The technology tackles historical challenges in clinical trials related to diversity, equity, and inclusion by removing traditional barriers such as cost, transportation, and access to medical records.
“Atropos Health is the fastest way to convert methodologically sound evidence from real-world data – for researchers, patient care, existing data platforms, and now, clinical development,” said Brigham Hyde, co-founder and CEO of Atropos Health.
“With SEQSTER, we add the ability not only to support analysis of registry data to the growing variety of real-world data sources available on the Atropos Health Evidence Network, but we can also support health system and life science customers’ ability to rapidly stand-up registries to support a variety of initiatives. Speed-to-setup and speed-to-insight through this combination is unprecedented and should drive critical evidence for underrepresented populations.”
The partnership and product announcement comes on the heels of Atropos Health entering the life sciences market earlier this year through a partnership with Janssen Research & Development, LLC. (Janssen). The company also launched its Geneva OS and ChatRWD user application, the first generative AI application incorporating direct chat-to-database capability, to help healthcare and life science leaders advance and accelerate evidence generation.
